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Mn-SOD/ Cu, Zn-SODmRNAwas assessed by Reverse Transcription
(RT)-PCR/ Taqman real-time PCR (q-PCR).
Results: Infection with Ct was found in Group I (13.7%; n=
20/145) patients, viz.: SSA and RSA (11/85 and 9/60, respectively),
whereas none of controls were infected (Group II). Qualitatively,
bothMn-SOD (p < 0.0001) andCu, Zn-SOD (p < 0.05) showedupreg-
ulated expression in Group I (Ct-infected SSA/ RSA) versus Group
II (control) patients; however, level of Mn-SOD was signiﬁcantly
increased (p<0.0001) incomparison toCu, Zn-SOD.Similarﬁndings
were obtained by qPCR analysis as there was signiﬁcant differen-
tial expression of transcript level of SODs, viz.:Mn-SOD (p < 0.0001)
and Cu, Zn-SOD (p < 0.05) in infected SSA/ RSA patients (Group I).
Ct-infected RSA showed elevatedMn-SOD expression (p < 0.001) as
compared to infected SSA. However, no signiﬁcant difference was
found in expression of Cu, Zn-SOD between infected patients, viz.:
RSA versus SSA.
Conclusion: The study suggested that superoxide radical and
its scavenging system play important role in maintenance of preg-
nancy in Ct-infected women. Overall results indicated that both
SODs are differentially expressed and Mn-SOD plays greater pro-
tective role in Ct-associated early abortion.
http://dx.doi.org/10.1016/j.ijid.2016.02.467
Type: Poster Presentation
Final Abstract Number: 41.281
Session: Poster Session I
Date: Thursday, March 3, 2016
Time: 12:45-14:15
Room: Hall 3 (Posters & Exhibition)
Hepatitis B and Human immunodeﬁciency virus
co-infection among pregnant women in
resource limited high endemic setting, Addis
Ababa, Ethiopia: Implications for current and
emerging prevention and control measures
Z.D. Woldesonbet
Addis Ababa University, Addis Ababa, Addis Ababa,
Ethiopia
Background: Pregnant women infected with hepatitis B virus
(HBV) and HIV can transmit the infection to their fetuses and
newborns. The study was intended to determine co-infection of
hepatitis B and Human immunodeﬁciency virus and assessing risk
factors among ANC visiting women.
Methods & Materials: A hospital based cross-sectional study
was employed from July to October, 2014 in a total of 215 preg-
nant women. Enzyme Linked Immunosorbent Assay kit was used
to detect HBV seromarker and HIV antibody in serum. Descrip-
tive andmultivariate logistic regressionwas performed and P<0.05
considered as indicator of statistical signiﬁcance.
Results: The prevalence of hepatitis B infection in the study
area was 6%. High HBV positivity was recorded among the age
group 25 –29 years. Many risk factors for HBV acquisition exists
in study settings, but amongst these, history of abortion (AOR=19;
CI=2.78-130.367; P-value=0.003), surgery (AOR=9.8; CI=1.392-
69.610); P-value=0.0.022) and tattooing (AOR=7.7; CI=1.185-50.28;
P-value=0.033 were signiﬁcantly associated with HBV infection.
The prevalence of HIV infection was 4.19% and none of the
socio-demographic and the risk factors were associated with HIV
positivity.
Conclusion: The prevalence of hepatitis B among in the study
area was intermediate and the prevalence of HIV/HBV co-infection
was 2 (22.2%). This may warrant patterns toward high infectivity
and therefore maximized risk of perinatal infection transmission.
These capitalize the demand to step up preventive efforts against
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Background: Yellow fever vaccine (YFV) had been considered
the safest of the live virus vaccines. But, Yellow fever vaccine - asso-
ciated neurotropic disease (YEL - AND), previously called as post
- vaccinial encephalitis is a known rare adverse reaction to this
vaccine.
Methods & Materials: A 30 years old hypertensive male pre-
sented to us with high grade intermittent fever, severe headache
& multiple episodes of vomitting three days after receipt of a 17D
strain live attenuated yellow fever vaccine at a government hospi-
tal. Onexaminationhehadneck stiffnesswithpositiveKernig’s sign
without any focal neurological deﬁcit. Hewaspreviously diagnosed
as having chronic kidney disease 3 mnths ago & was on medical
follow up.
Results: Blood investigations showed anormal hemogram, liver
function tests and a borderline raised creatinine (1.8 mg/dL). Blood
investigations sent for the endemic tropical diseases like malaria,
dengue& leptospirosis cameout negative. Cerebrospinal ﬂuid (CSF)
was suggestive of viral meningitis (protein 101 mg/dL, sugar 50
mg/dL, total cells 82) with lymphocyte predominance. His CSF cul-
ture showed no growth. MRI Brain was normal. He was treated
symptomatically. His symptoms resolved over next 2-3 days & he
was discharged without any focal neurological deﬁcit. We believe
that he suffered a rare complication of yellow fever vaccine - YEL-
AND since no other cause was found.
Conclusion: The two important complications of YFV are YEL-
AND & Yellow fever vaccine associated viscerotropic disease (YEL
– AVD).
The incidence of YEL - AND in United States is 0.8 per 1,00,000
doses administered. It represents a conglomerate of clinical syn-
dromes, including meningoencephalitis, Guillain-Barré syndrome,
acute disseminated encephalomyelitis, and rarely, cranial nerve
palsies. The onset of illness for documented cases is 3–28 days after
vaccination. It is rarely fatal & is treated symptomatically.
http://dx.doi.org/10.1016/j.ijid.2016.02.469
